上海交通大学医学院研究生导师简介冉志华

删除或更新信息，请邮件至freekaoyan#163.com(#换成@)

上海交通大学免费考研网/2013-01-10

基本信息

导师姓名:	冉志华	专业代码:	100201
性别:	男	专业名称:	内科学
培养单位:	仁济医院	三级学科/ 专业领域:	消化系病
导师类型:	博士生导师	专业学位导师:	兼
联系方式:	zhihuaran@vip.163.com 上海市东方路1630号仁济医院消化科;邮编200127电话: 021-68383114

研究方向 (点击浏览详细信息)

炎症性肠病基础与临床研究

社会任职

中华医学会消化病学分会炎症性肠病学组副组长，上海市医学会消化病学分会委员兼炎症性肠病学组组长，中华医学科技进步奖第二届评审委员会委员，国家自然科学基金委同行评审专家,Journal of Digestive Disease基金会共同理事长。Journal of Digestive Disease杂志执行编辑、《中华消化杂志》、《胃肠病学》、《国际消化病学》等杂志编委, 为《British Medical journal》、《Alimentary Pharmacology & Therapeutics》、《Journal of Clinical Pharmacy and Therapeutics》、《Journal of Gastroenterology and Hepatology》、《Journal of Cellular Biochemistry》、《Digestive Diseases and Sciences》、《Cancer Chemotherapy Pharmacology》、《Journal of Digestive Disease》、《Chinese Medical Journal》等9本SCI、3本中文杂志特约审稿人。

担任上海市消化疾病研究所副所长、卫生部内科消化重点实验室副主任、仁济医院大内科常务副主任、仁济医院消化科副主任、仁济临床医学院内科学教研室主任

科研项目

项目编号	项目名称	课题来源	起止时间	科研经费	承担职责
2012BAI06B00	<炎症性肠病的分子分型诊断及个体化治疗方案研究>子项目“IBD特异性易感基因和发病相关肠道菌群研究”	国家科技部	2012-01~~2015-12	39万元	课题参与人
81170362	克罗恩病基于分化动力学平衡偏移的CREB相关长链非编码RNA变异机制研究	国家自然科学基金委,面上项目	2012-01~~2015-12	55万元	主要责任人
10XD1402600	DNA拷贝数变异与克罗恩病的关联研究	上海市科委优秀学科带头人	2010-04~~2012-03	40万元	主要责任人
RJ41014305	炎症性肠病诊治学科群	仁济医院学科建设	2010-01~~2012-12	50万元	主要责任人
30770964	miRNA在人结肠癌细胞羟基喜树碱多药耐药中的作用初探	国家自然基金委,面上项目	2008-01~~2010-12	30万元	课题负责人
200802156	中国炎症性肠病易感基因的筛选与临床研究	卫生部行业基金	2008-01~~2010-12	17万元	子课题负责人
06DZ22027	人结肠多耐药机制及耐药逆转研究	上海市科委,重点实验室	2007-01~~2009-12	40万元	课题负责人
30670942	HRP蛋白在人结肠癌多药耐药过程中的作用及其分子机制研究	国家自然基金委,面上项目	2007-01~~2009-12	8万元	课题负责人
2002-17	Investigation of the relationship between differentiation state of gastric cancer and their susceptibility to parvovirus H-1 induced killing	上海市科委白玉兰基金	2002-09~~2003-03	1万元	课题负责人
交流项目	The role of MAPK signaling pathways in parvovirus oncolytic activity	第五届中德生物技术合作项目	2002-07~~2004-06	万元	课题负责人
	胃癌细胞分化状态与细小病毒毒性作用相关性的研究	国家教委青年骨干项目	2000-01~~2002-12	12万元	课题负责人
grant I/75 890	Investigation of the relationship between differentiation state of gastric cancer and their susceptibility to parvovirus H-1 induced killing	德国大众基金会	2000-01~~2002-12	20万德国马克万元	课题负责人

学术论文 (#为通讯作者,*为共同第一作者)

1、Tong JL, Huang ML, Xu XT, Qiao YQ, Ran ZH.#. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: A meta-analysis.. J Dig Dis.,2012;Apr;13(4):200-7
2、Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD, Ran ZH. #. MicroRNA Expression Profiling Identifies miR-328 regulates Cancer Stem Cell-Like SP Cells in Colorectal Cancer. Br J Cancer,2012;Mar 27;106(7):1320-30
3、Zhu MM, Tong JL, Xu Q, Nie F, Xu XT, Xiao SD, Ran ZH.#. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer. PLoS One,2012;7(8) : e41763.
4、Jin Lu Tong, Chen Peng Zhang, Fang Nie, Xi Tao Xu, Ming Ming Zhu, Shu Dong Xiao, Zhi Hua Ran#. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Letter,2011;585:3560-3568
5、Zhong M, Dong XW, Zheng Q, Tong JL, Ran ZH#. MicroRNA 506 regulates expression of Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): A meta-analysis. Thromb Res,2011;Nov;128(5):403-9
6、Shen Jun, Qian Xiaoxian, Ran Zhihua#, Tong Jinlu, Qiao Yuqi and Huang Meilan. Activated expression of CD27-CD70 co-stimulatory molecules in inflamed and non-inflamed tissues of intestinal mucosa in patients with inflammatory bowel disease. Sci Res Essays,2011;Fub;6(4): 793–798
7、Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH#, Xiao SD. Meta-analysis: Circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis,2011; Aug;12(4):234-44
8、Xu Q, Yang CH, Liu Q, Jin XF, Xu XT, Tong JL, Xiao SD, Ran ZH#. Chemopreventive effect of epigallocatechin-3-gallate (EGCG) and folic acid on the N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced gastrointestinal cancer in rat model. J Dig Dis,2011;Jun;12(3):181-7
9、Huang ML, Ran ZH#, Shen J, Li XB, Xu XT, Xiao SD. Efficacy and safety of adalimumab in Crohn's disease: Meta-analysis of placebo-controlled trials. J Dig Dis,2011;Jun;12(3):165-72
10、Zhu MM、Xu XT、Nie F、Tong JL、Xiao SD、Ran ZH. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis,2011;Aug;26(8):999-1007
11、Chen X, Ran ZH#, Tong JL, Nie F, Zhu MM, Xu XT, Xiao SD. RNA interference (RNAi) of Ufd1 protein can sensitize a hydroxycamptothecin-resistant colon cancer cell line SW1116/HCTP to hydroxycamptothecin. J Dig Dis,2011;12;110-116
12、Zhu MM, Lu H#, Wang TR, Zheng Q, Ran ZH. Concurrent amoebic and Klebsiella pneumoniae liver abscess in an immunocompetent patient: An unusual case report and review of the literature. J Dig Dis,2010;11;249-253
13、Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH#. Thiopurine S - methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroentero,2010;Jul 7;16:3187-95
14、Zhu MM, Xu XT, Nie F, Tong JL, Xiao SD, Ran ZH#. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis,2010;11:148-60
15、Fang NIE, Jun SHEN, Jin Lu TONG, Ming Ming ZHU, Xi Tao XU & Zhi Hua RAN. Meta-analysis : the efficacy and the safety of monoclonal antibody targeted to epidermal growth factor receptor (EGFR) in the treatment of the patients with metastatic colorectal cancer (mCRC). J Dig Dis,2009;10：247–257
16、Jun Shen, Zhi Hua Ran#, Yao Zhang, Qing Cai, Hong Min Yin, Xiao Tian Zhou, Shu Dong Xiao. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo Biomarkers of altered coagulation fibrinolysis as measures of disease activity in active inflammatory bowel disease: a gender-stratified cohort analysis. Thrombosis research,2009;123:604-611
17、J Shen、Z H Ran、H M Yin、X T Zhou and S D Xiao. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. Internal Medicine Journal,2009;39: 103-109
18、J.L.Tong, Z.H.Ran#, J.Shen, S.D.Xiao. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Phar Ther,2009;34:41-53
19、Zhi Hua RAN#, Yao Zong YUAN, Zhao Shen LI, et al. Sequential therapy vs. standard triple The efficacy of combizym in the treatment of Chinese patients with dyspepsia: a multicenter, randomized, placebo-controlled and cross-over study. J Dig Dis,2009;10:41-48
20、Tong JL, Ran ZH#, Shen J, Fan GQ, Xiao SD. Association between Fecal Bile Acids and Colorectal Cancer: A Meta-analysis of Observational Studies. Yonsei Med J,2008;49:792-803
21、Jun Shen, Zhi Hua Ran#, Jin Lu Tong, Xiang Chen, Shu Dong Xiao. Endoscopic grading and scoring systems in inflammatory bowel disease are they the same？. Saudi Medical Journal,2008;10:41-48
22、Zhi Hua Ran#, Chi chen, Shu dong Xiao. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomedicine et Pharmacotherapy. Biomedicine et Pharmacotherapy,2008;62: 189-196
23、J. SHEN, Z. H. RAN#, J. L. TONG & S. D. XIAO. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther,2007;26:653-663
24、J. L. TONG, Z. H. RAN#, J. SHEN, C.X.ZHANG, S.D.XIAO. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther,2007;25:155-168
25、Xiang Chen, Zhi Hua Ran#, Jin Lu Tong. A meta-analysis of the yield of capsule endoscopy compared to double-balloon enteroscopy in patients with small bowel diseases. World J Gastroenterol,2007;13:4372-4378
26、Zhi Hua RAN#, Qi XU, Jin Lu TONG, Shu Dong XIAO. Apoptotic effect of Epigallocatechin-3-gallate on human gastric cancer cell line MKN45 via the activation of mitochondrial pathway. World J Gastroenterol,2007;13:4255-4259
27、Qin CAO, Zhi Hua RAN#, Shu Dong XIAO. Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis,2007;8:15-22
28、J. L. TONG, Z. H. RAN#, J. SHEN, C.X.ZHANG, S.D.XIAO. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther,2007;25:155-168
29、Xiao Shudong and Ran Zhihua. Recent advances in molecular biology of gastric carcinogenesis. Chin Med J,2003; 116(1): 3-4
30、Zhi Hua Ran#, Beatrice Rayet, Jean Rommelaere, and Steffen Faisst. Parvovrius H-1 induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Research,1999;65(1999)161-174